[Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?].

A TRUE THERAPEUTIC REVOLUTION OR A TREND? Psychedelics, long marginalized, are now gaining renewed interest in psychiatry for their therapeutic potential. Substances like psilocybin, LSD, and MDMA are being studied for treating conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), and anxiety in palliative care. The FDA granted psilocybin "breakthrough therapy" status for certain indications in psychiatry, and progress has been made in Phase 3 clinical trials. However, the use of psychedelics carries risks, especially with non-medical use, including side effects. Stigmatization, their illegal status in many countries, and high costs limit accessibility. Despite promising results, the integration of these substances in psychiatry remains uncertain and raises ethical and societal concerns.